Posted by Michael Wonder on 21 Dec 2022
Iveric Bio announces completion of rolling NDA submission to FDA for avacincaptad pegol for the treatment of geographic atrophy
20 December 2022 - Commercial launch preparations continue to accelerate.
IVERIC bio today announced that it has submitted to the US FDA the third and final part of its new drug application for rolling review of avacincaptad pegol, a novel investigational complement C5 inhibitor for the treatment of geographic atrophy secondary to age-related macular degeneration.
